First patient dosed in Australia where 3 clinical trial sites have been activated. The trial will enrol advanced colorectal cancer patients whose cancer...
LEQEMBI obtained manufacturing and marketing approval for the indication of slowing progression of mild cognitive impairment (MCI) and mild dementia due to...
This partnership leverages Taiwan Bio’s world-class expertise in cellular therapy manufacturing and TRACT Therapeutics’ innovative immune modul...
The Healthcare+ Expo Taiwan, currently taking place at Nangang Exhibition Hall 1 from November 30 to December 3, 2023, is poised to redefine the landscape ...
For the first-line treatment of adults with metastatic or recurrent locally advanced nasopharyngeal carcinoma (NPC), and for toripalimab, as a single agent...
This development underscores the company's commitment to advancing innovative solutions that provide relief and improved quality of life for the millions o...
This site expansion will support faster enrolment in this cost-efficient, investigator-initiated study evaluating eftilagimod alpha (efti) in combination w...
CMI Inc. and Life Molecular Imaging (LMI) are pleased to announce that the amyloid-PET diagnostic Neuraceq® (florbetaben 18F injection) has ...
This marks a significant milestone as XEOMIN® is the first approved neurotoxin for the treatment of this condition in the Australian market. Additional...
GBM AGILE Adaptive Platform Trial Recruiting in Australia Austin Health in Melbourne and Royal North Shore Hospital in Sydney are Now Enrolling Patients ...
Funds to support translation of R&D programs derived from proprietary NetMAPPR machine learning network biology platform and CombiGEM combinatorial gen...
– Risk of death was reduced by 53% in patients treated with enfortumab vedotin plus pembrolizumab compared to chemotherapy – – Enfo...
To support emerging precision therapies and improve patient outcomes by increasing access to reliable genomic testing needed to match patients with targete...
Fezolinetant is an investigational nonhormonal treatment for vasomotor symptoms (VMS) associated with menopause More than half of women ages 40 to 64 wor...
© 2025 Biopharma Boardroom. All Rights Reserved.
